# US 2025/0032430 A1 · Uses of rhodoquinone for the treatment of disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0032430 A1
- Document ID: US20250032430A1
- Status: Published application
- Kind: A1
- Application number: 18/706,551
- Filed: 2022-11-02
- Published: 2025-01-30
- Earliest claimed: 2021-11-02
- Assignees: Whitehead Institute for Biomedical Research; University of Massachusetts
- Applicants: Whitehead Institute for Biomedical Research; University of Massachusetts
- Inventors: David M. Sabatini; Jessica Spinelli
- Web page: https://patentgrep.com/patent/US20250032430A1

## CPC

- A61K 31/136: having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- A61P 3/06: Antihyperlipidemics
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 39/06: Free radical scavengers or antioxidants
- C07C 217/84: the oxygen atom of at least one of the etherified hydroxy groups being further bound to an acyclic carbon atom
- C07C 225/28: of non-condensed quinone rings
- C07C 2601/16: the ring being unsaturated
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Provided herein are compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. Also provided are methods, uses, and kits involving the disclosed compounds and pharmaceutical compositions thereof for treating and/or preventing a disease (e.g., a metabolic disorder (e.g., obesity, diabetes), a hypoxia related disease (e.g., a proliferative disease, inflammatory disease, neuromuscular disorder, neurodegenerative disorder, hypoxia, ischemia, oxidative stress, or a mitochondrial DNA related disorder), or a disease resulting from rhodoquinone depletion (e.g., a proliferative disease, inflammatory disease, neuromuscular disorder, metabolic disorder, or neurodegenerative disorder)) in a subject.

## Claims

### Claim 1

A method of treating a disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula (I):
wherein n=1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof;
wherein the disease is a metabolic disorder, hypoxia related disease, or a disease resulting from rhodoquinone depletion.

### Claim 2

A method of treating a disease resulting from rhodoquinone depletion in a subject in need thereof, the method comprising:
administering to the subject a therapeutically effective amount of a compound of Formula (I):
wherein n=1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof;
wherein the subject has previously been administered a statin.

### Claim 3

A method of treating a disease in a subject in need thereof, the method comprising:
administering to a subject in need thereof an agent or therapy that increases the level of a compound of Formula (I):
wherein n=1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, in the subject;
wherein the disease is a metabolic disorder, hypoxia related disease, or a disease resulting from rhodoquinone depletion.

### Claim 4 (depends on 3)

The method of claim 3, wherein the therapy is a gene therapy.

### Claim 5

A method of treating a disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound of Formula (II):
wherein m=1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof;
wherein the disease is a metabolic disorder, hypoxia related disease, or a disease resulting from rhodoquinone depletion.

### Claim 6

A method of treating a disease resulting from rhodoquinone depletion in a subject in need thereof, the method comprising:
administering to the subject a therapeutically effective amount of a compound of Formula (II):
wherein m=1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof;
wherein the subject has previously been administered a statin.

### Claim 7

A method of treating a disease in a subject in need thereof, the method comprising:
administering to a subject in need thereof an agent or therapy that increases the level of a compound of Formula (II):
wherein m=1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof; in the subject;
wherein the disease is a metabolic disorder, hypoxia related disease, or a disease resulting from rhodoquinone depletion.

### Claim 8 (depends on 7)

The method of claim 7, wherein the therapy is a gene therapy.

### Claim 9 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein n is 8, 9, 10, or 11.

### Claim 10 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein n is 9 or 10.

### Claim 11 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein n is 9.

### Claim 12 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein n is 10.

### Claim 13 (depends on 5, 6, 7, 8)

The method of any one of claims 5-8, wherein m is 8, 9, 10, or 11.

### Claim 14 (depends on 5, 6, 7, 8)

The method of any one of claims 5-8, wherein m is 9 or 10.

### Claim 15 (depends on 5, 6, 7, 8)

The method of any one of claims 5-8, wherein m is 9.

### Claim 16 (depends on 5, 6, 7, 8)

The method of any one of claims 5-8, wherein m is 10.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 1-16, wherein the subject is a mammal.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The method of any one of claims 1-17, wherein the subject is a human.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, wherein the disease is a metabolic disorder.

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 1-19, wherein the disease is obesity.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19)

The method of any one of claims 1-19, wherein the disease is diabetes.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, wherein the disease is ischemia.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, or 22, wherein the ischemia is ischemia of the pancreas, adipose tissue, skeletal muscle, brain, kidney, liver, gastrointestinal tract, heart, or lung.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, or 22-23, wherein the ischemia is ischemia of the pancreas.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, or 22-23, wherein the ischemia is ischemia of the adipose tissue.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, or 22-23, wherein the ischemia is ischemia of the skeletal muscle.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, or 22-23, wherein the ischemia is ischemia of the brain.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, or 22-23, wherein the ischemia is ischemia of the kidney.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, or 22-23, wherein the ischemia is ischemia of the liver.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, or 22-23, wherein the ischemia is ischemia of the gastrointestinal tract.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, or 22-23, wherein the ischemia is ischemia of the heart.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, or 22-23, wherein the ischemia is ischemia of the lung.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, wherein the disease is hypoxia.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, or 33, wherein the disease is exercise-induced hypoxia.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, or 33, wherein the disease is hypoxia resulting from ischemia.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, or 33-35, wherein the hypoxia is hypoxia of the heart.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, or 33-35, wherein the hypoxia is hypoxia of the lung.

### Claim 38 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, wherein the disease is oxidative stress.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, wherein the disease is a neuromuscular disorder.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, or 39, wherein the neuromuscular disorder is a mitochondrial myopathy.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, wherein the disease is a neurodegenerative disorder.

### Claim 42 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, or 41, wherein the neurodegenerative disorder results from mutations in the mitochondrial DNA.

### Claim 43 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, wherein the disease is CoQ10 deficiency.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, wherein the disease is mitochondrial complex 3 deficiency.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, wherein the disease is mitochondrial complex 4 deficiency.

### Claim 46

A composition comprising a therapeutically effective amount of a compound of Formula (I):
wherein n=1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, and an additional pharmaceutical agent.

### Claim 47 (depends on 46)

The composition of claim 46, wherein n=8 or 9.

### Claim 48

A composition comprising a therapeutically effective amount of a compound of Formula (II):
wherein m=1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, and an additional pharmaceutical agent.

### Claim 49 (depends on 48)

The composition of claim 48, wherein m=8 or 9.

### Claim 50 (depends on 46, 47, 48, 49)

The composition of any one of claims 46-49, wherein the additional pharmaceutical agent is an anti-obesity agent.

### Claim 51 (depends on 46, 47, 48, 49)

The composition of any one of claims 46-49, wherein the additional pharmaceutical agent is a probiotic.

### Claim 52 (depends on 46, 47, 48, 49)

The composition of any one of claims 46-49, wherein the additional pharmaceutical agent is an antibiotic.

### Claim 53 (depends on 46, 47, 48, 49)

The composition of any one of claims 46-49, wherein the additional pharmaceutical agent is a statin.

### Claim 54

A compound of Formula (I):
wherein n=1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, for use in treating a disease in a subject in need thereof;
wherein the disease is a metabolic disorder, hypoxia related disease, or a disease resulting from rhodoquinone depletion.

### Claim 55

A compound of Formula (I):
wherein n=1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, for use in the manufacture of a medicament for the treatment of a disease in a subject in need thereof;
wherein the disease is a metabolic disorder, hypoxia related disease, or a disease resulting from rhodoquinone depletion.

### Claim 56

Use of a compound of Formula (I):
wherein n=1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, for treating a disease in a subject in need thereof;
wherein the disease is a metabolic disorder, hypoxia related disease, or a disease resulting from rhodoquinone depletion.

### Claim 57

A compound of Formula (II):
wherein m=1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, for use in treating a disease in a subject in need thereof;
wherein the disease is a metabolic disorder, hypoxia related disease, or a disease resulting from rhodoquinone depletion.

### Claim 58

A compound of Formula (II):
wherein m=1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, for use in the manufacture of a medicament for the treatment of a disease in a subject in need thereof;
wherein the disease is a metabolic disorder, hypoxia related disease, or a disease resulting from rhodoquinone depletion.

### Claim 59

Use of a compound of Formula (II):
wherein m=1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof, for treating a disease in a subject in need thereof;
wherein the disease is a metabolic disorder, hypoxia related disease, or a disease resulting from rhodoquinone depletion.

### Claim 60 (depends on 54, 55, 56)

The compound or use of any one of claims 54-56, wherein n is 9 or 10.

### Claim 61 (depends on 54, 55, 56)

The compound or use of any one of claims 54-56, wherein n is 9.

### Claim 62 (depends on 54, 55, 56)

The compound or use of any one of claims 54-56, wherein n is 10.

### Claim 63 (depends on 57, 58, 59)

The compound or use of any one of claims 57-59, wherein m is 9 or 10.

### Claim 64 (depends on 57, 58, 59)

The compound or use of any one of claims 57-59, wherein m is 9.

### Claim 65 (depends on 57, 58, 59)

The compound or use of any one of claims 57-59, wherein m is 10.

### Claim 66 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The compound or use of any one of claims 54-65, wherein the disease is a metabolic disorder.

### Claim 67 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The compound or use of any one of claims 54-66, wherein the disease is obesity.

### Claim 68 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The compound or use of any one of claims 54-65, wherein the disease is ischemia.

### Claim 69 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The compound or use of any one of claims 54-65, or 68, wherein the ischemia is ischemia of the kidney, liver, gastrointestinal tract, heart, or lung.

### Claim 70 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The compound or use of any one of claims 54-65, or 68-69, wherein the ischemia is ischemia of the heart.

### Claim 71 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The compound or use of any one of claims 54-65, or 68-69, wherein the ischemia is ischemia of the lung.

### Claim 72 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The compound or use of any one of claims 54-65, wherein the disease is hypoxia.

### Claim 73 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The compound or use of any one of claims 54-65, or 72, wherein the hypoxia is hypoxia of the kidney, liver, gastrointestinal tract, heart, or lung.

### Claim 74 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The compound or use of any one of claims 54-65, or 72-73, wherein the hypoxia is hypoxia of the heart.

### Claim 75 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The compound or use of any one of claims 54-65, or 72-73, wherein the hypoxia is hypoxia of the lung.

### Claim 76 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The compound or use of any one of claims 54-65, or 72-75, wherein the disease is exercise-induced hypoxia.

### Claim 77 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The compound or use of any one of claims 54-65, or 72-76, wherein the disease is hypoxia resulting from ischemia.

### Claim 78 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The compound or use of any one of claims 54-77, wherein the disease is oxidative stress.

### Claim 79 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The compound or use of any one of claims 54-65, wherein the disease is a neuromuscular disorder.

### Claim 80 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The compound or use of any one of claims 54-65, or 79 wherein the neuromuscular disorder is a mitochondrial myopathy.

### Claim 81 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The compound or use of any one of claims 54-65, wherein the disease is a neurodegenerative disorder.

### Claim 82 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The compound or use of any one of claims 54-65, or 81, wherein the neurodegenerative disorder results from mutations in the mitochondrial DNA.

### Claim 83 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The compound or use of any one of claims 54-65, wherein the disease is CoQ10 deficiency.

### Claim 84 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The compound or use of any one of claims 54-65, wherein the disease is mitochondrial complex 3 deficiency.

### Claim 85 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The compound or use of any one of claims 54-65, wherein the disease is mitochondrial complex 4 deficiency.

### Claim 86 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85)

A composition comprising a compound of any one of claims 54-85; and
an additional pharmaceutically acceptable excipient.

### Claim 87

A kit comprising:
a compound of Formula (I):
wherein n=1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof; and
instructions for using the compound, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof.

### Claim 88

A kit comprising:
a compound of Formula (II):
wherein m=1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12; or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof; and
instructions for using the compound, or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof.

### Claim 89 (depends on 87, 88)

The kit of claim 87 or 88, further comprising an additional pharmaceutical agent.

### Claim 90 (depends on 87, 88, 89)

The composition or kit of any one of claims 87-89, wherein the additional pharmaceutical agent is an anti-obesity agent.

### Claim 91 (depends on 87, 88, 89)

The composition or kit of any one of claims 87-89, wherein the additional pharmaceutical agent is a probiotic.

### Claim 92 (depends on 87, 88, 89)

The composition or kit of any one of claims 87-89, wherein the additional pharmaceutical agent is an antibiotic.

### Claim 93 (depends on 87, 88, 89)

The composition or kit of any one of claims 87-89, wherein the additional pharmaceutical agent is a statin.

### Claim 94 (depends on 87, 88, 89)

The composition or kit of any one of claims 87-89, wherein the additional pharmaceutical agent is a plasmid.
